Clarification of EMEA (European Medicines Evaluation Agency) role in device approvals sought
This article was originally published in Clinica
Executive Summary
Medical device manufacturers who have become frustrated by what they see as the European Agency for the Evaluation of Medicinal Products' over-involvement in the evaluation of medical devices containing derivatives of human blood or plasma can now hope for some clarification of the EMEA's role.
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.